Matthew Gallagher built Medvi, a GLP-1 telehealth startup, in two months with $20,000 and more than a dozen AI tools including ChatGPT, Claude, and Grok. The company hit $401 million in sales in 2025 with 250,000 customers and a 16.2% net profit margin, and is tracking toward $1.8 billion in 2026 revenue with just two employees. The New York Times verified the financials. submitted by /u/alvivanco1
Originally posted by u/alvivanco1 on r/ArtificialInteligence
Critics have noted that Medvi’s growth owes as much to the GLP-1 market’s demand surge as to the AI toolkit. Gallagher chose a sector with desperate customers, built an interface connecting them to prescription providers, executed aggressive marketing, and scaled fast. The AI tools handled functions that would normally require a team, but the market did the heavy lifting on demand.
OpenLoop CEO Jon Lensing, one of Gallagher’s key partners, told the New York Times: “Matthew’s native tongue seems to be A.I.”
For solo founders, the operational model is the story: one person using AI agents to run code, copy, ads, customer service, and analytics, while outsourcing compliance and fulfillment to specialized partners. Whether Medvi’s revenue trajectory holds depends on regulatory and competitive dynamics in the GLP-1 space, but the company formation pattern is already being replicated.